Recall archive / FDA drug enforcement

Helix Tri-Active Therapy Cream (Camphor 3.2%, Menthol 7.4%, Methyl salicylate 12.5%), packaged in a) 3 fl. oz. roll-o... — FDA record D-1091-2023

Reported terminated

Status as reported in the agency record. FDA warns that enforcement status may not track the current recall lifecycle; check the current official notice.

Source date Aug 2, 2023. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.

Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.

What the record says

Product: Helix Tri-Active Therapy Cream (Camphor 3.2%, Menthol 7.4%, Methyl salicylate 12.5%), packaged in a) 3 fl. oz. roll-on (NDC 30775-052-03) and b) 4 fl. oz. tube (NDC 30775-052-04) Parker Laboratories, Inc. 286 Eldridge Road, Fairfield, NJ 07004
Reason: CGMP Deviations
Classification: Class II
Recalling firm: Parker Laboratories, Inc.
Quantity: 8
Agency-reported status: Terminated
Source record identifier: D-1091-2023

Open the official record

What the recall classes mean. Classification is an agency assessment, not individual medical advice.

Lot and product identifiers

Label field	Details supplied by the agency
Lot, code or applicability	Lot #: a) A1221010, Exp. Date 12/9/2023, b) A1221011, Exp date 12/9/2023

Match all identifying details in the current notice. A brand name alone is not enough.

Distribution

Nationwide within the United States, Singapore, Korea and Hong Kong

States below are derived from the distribution text, including nationwide wording. They are not inferred from the firm's address.

Dates in the source

Report date: Aug 30, 2023
Recall initiation date: Aug 2, 2023
Center classification date: Aug 18, 2023
Termination date: Jun 3, 2024

FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.